ZETAMET
Live / Registered — Registered (as of 10 Feb 2026)
What this means for you
Registered since 10 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97054481
- Registration number
- 8137565
- Mark type
- Stylized text
- Filed
- 30 Sept 2021
- Published for opposition
- 02 Aug 2022
- Registered
- 10 Feb 2026
- Attorney of record
- Katherine P. Califa
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of metastatic tumors and lesions; Pharmaceuticals, namely, for destroying, inhibiting or preventing the spread of uncontrolled growth of abnormal tissues, namely, metastatic tumors and lesions
Owner
- Zetagen Therapeutics, Inc., Syracuse, NY, US
- Zetagen Therapeutics, Inc., Syracuse, NY, US
- Zetagen Therapeutics, Inc., Syracuse, NY, US
Prosecution history
- 10 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
- 22 Jan 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 22 Jan 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Jan 2026 — NON-FINAL ACTION E-MAILED
- 13 Jan 2026 — SU - NON-FINAL ACTION - WRITTEN
- 12 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Jan 2026 — ASSIGNED TO LIE
- 29 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 29 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 29 Sept 2025 — NON-FINAL ACTION E-MAILED
- 29 Sept 2025 — SU - NON-FINAL ACTION - WRITTEN
- 26 Sept 2025 — STATEMENT OF USE PROCESSING COMPLETE